REGISTER
Diabetes at IDF-WPR 2026: Nine Studies from Profs. Lixin Guo and Qi Pan
At IDF-WPR 2026 in Melbourne, Prof. Lixin Guo and Prof. Qi Pan of Beijing Hospital presented nine diabetes studies. Key findings include the ReTARdant real-world DPNP prescribing study, a 5:2 intermittent-fasting trial outperforming metformin and empagliflozin on TyG index, and UK Biobank data linking ≥6 controlled risk factors to 60% lower limb-ulcer risk. The program also covered an OAS/RNase L-METTL3-TXNIP wound-healing axis and a C-peptide threshold for small-fiber neuropathy.

Introduction

From 18-21 August 2026, the IDF World Congress Region Western Pacific 2026 (IDF-WPR 2026), the Australian Diabetes Congress 2026 (ADC 2026), and the Metabolic Diseases 2026 congress were held in Melbourne, Australia. Among the contributions, the team led by Prof. Lixin Guo and Prof. Qi Pan from the Department of Endocrinology, Beijing Hospital / National Center of Gerontology, presented nine research studies—four oral presentations and five posters—covering complications management, novel treatment strategies, pathogenesis, and obesity care. The highlights are summarized below.

Diabetes and Its Complications

Poster 1. Real-World Pharmacologic Treatment Patterns in Chinese Patients With Diabetic Peripheral Neuropathic Pain: The ReTARdant Study

Authors: Qi Pan, Haining Wang, Jianling Du, Yongbo Wang, Xuefeng Yu, Zhelong Liu, Sunjie Yan, Yongze Zhang, Xiaohong Wu, Ye Hu, Yingchun Zhang, Juan Du, Mengqi Liu, Bifa Fan, Lixin Guo

Background: Diabetic peripheral neuropathic pain (DPNP) is associated with depression, sleep disturbance, and impaired daily functioning. International and Chinese guidelines recommend serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and calcium channel ligands (CaL) such as pregabalin and gabapentin as first-line therapy; tramadol and other opioids are reserved for second- or third-line use. Real-world data on DPNP medication patterns in China had been limited.

Methods: This multicenter, retrospective observational study (NCT06546202) drew on electronic medical records (2017-2022) of adult DPNP patients from five Chinese hospitals (2018-2021). Analyses used the full analysis set (FAS); missing data were not imputed.

Results: 820 patients were included (mean age 61.3; 70.5% treatment-naive). Initial therapy was dominated by neuropathic pain drugs (NeuD) (94.5%), NSAIDs (58.5%), and CaL (22.6%); combination therapy was used in 65.1% of cases, with NSAIDs + NeuD the most common regimen (40.6%). Over follow-up, 98.2% discontinued therapy, 14.2% switched agents, and 7.2% added agents. Median time to discontinuation was 21 days (30-day cumulative rate 56.9%); median time to switch was 19.6 months (12-month cumulative rate 37.6%); median time to add-on was 43.6 months (12-month cumulative rate 19.0%). Proportion of days covered (PDC) ≥80% was: pregabalin 34.0%, gabapentin 48.2%, duloxetine 46.2%, tramadol 50.0%.

Conclusions: In Chinese DPNP patients, NeuD, NSAIDs, and CaL are the most frequently prescribed drug classes, and most patients start on combination therapy. The discontinuation rate during follow-up is high, and switching mostly occurs between NSAIDs and NeuD, with relatively few patients transitioning to regimens containing CaL or SNRIs.

Oral 1. Effects of 5:2 Intermittent Fasting Meal Replacement on the TyG Index and Insulin Resistance in Early T2DM With Metabolic Syndrome: A Secondary Analysis of a Randomized Controlled Trial

Authors: Dongni Yu, Huijuan Yuan, Guijun Qin, Shuchun Chen, Yue Xi, Wenbo Jin, Lihui Zhang, Yu Liu, Yu Cheng, Xingbo Cheng, Qi Pan, Lixin Guo

Background: The EARLY study had shown that 5:2 intermittent fasting meal replacement (5:2 MR) outperformed metformin or empagliflozin for glycemic control and weight loss in early T2DM, but the conventional Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) had not shown a clear advantage. The triglyceride-glucose (TyG) index, a more sensitive marker of glucose-lipid interaction, was therefore evaluated in this secondary analysis.

Methods: A multicenter, open-label, randomized controlled trial enrolled newly diagnosed T2DM adults with BMI ≥24 kg/m² and disease duration under one year. Participants were randomized to 5:2 MR, metformin, or empagliflozin for 16 weeks. The 5:2 MR protocol specified two non-consecutive low-calorie days per week (women 500 kcal / men 600 kcal via meal replacement) plus replacement of dinner with meal replacement on the remaining five days. This analysis focused on 323 participants meeting the International Diabetes Federation (IDF) metabolic syndrome (MetS) criteria. The primary outcome was change in TyG index; secondary outcomes included HOMA-IR, fasting insulin, C-peptide, blood glucose, anthropometrics, blood pressure, and lipids. Between-group differences were assessed by analysis of covariance.

Results: After 16 weeks, the 5:2 MR group (n=104) showed a significantly greater reduction in TyG index than metformin (n=107) or empagliflozin (n=112), with least-squares mean differences (LSM) of -0.52 (95% CI, -0.68 to -0.37) and -0.51 (95% CI, -0.67 to -0.35), respectively (both P<0.001). 5:2 MR was also associated with greater improvements in HOMA-IR, fasting insulin, C-peptide, HbA1c, BMI, waist circumference, blood pressure, triglycerides, and HDL cholesterol than either drug (all P≤0.018). No significant difference was observed between metformin and empagliflozin.

Conclusions: In this analysis, a 16-week 5:2 MR regimen appeared to outperform metformin or empagliflozin monotherapy for improving TyG index, insulin resistance, and multiple cardiometabolic risk factors in adults with overweight/obesity, early T2DM, and MetS. The 5:2 MR regimen may be considered an effective treatment strategy in this high-risk population, and TyG index may serve as a sensitive marker of treatment response.

Oral 2. OAS/RNase L Pathway Activation Promotes Endothelial Pyroptosis and Impairs Diabetic Wound Healing via Regulation of TXNIP m6A Methylation

Authors: Yating Huang, Qi Pan, Lixin Guo

Objective: Diabetic skin may show aberrant activation of antiviral enzymes even in the absence of infection, but the pathological significance has been unclear. This study examined whether sustained activation of the OAS/RNase L pathway under hyperglycemia contributes to endothelial pyroptosis and impaired diabetic wound healing.

Methods: Human umbilical vein endothelial cells (HUVECs) were cultured under high glucose and stimulated with lipopolysaccharide (LPS) to mimic diabetic inflammatory stress. Small interfering RNA (siRNA) was used to knock down RNase L. In vitro, OAS/RNase L pathway activity, pyroptosis markers, METTL3 expression, and thioredoxin-interacting protein (TXNIP) mRNA m6A methylation and TXNIP expression were measured. In vivo, streptozotocin (STZ)-induced diabetic mice received oral ellagic acid (EA), an RNase L inhibitor, and skin pyroptosis and wound healing were evaluated.

Results: High glucose induced aberrant OAS/RNase L pathway activation in HUVECs and markedly amplified LPS-driven pyroptosis. Silencing RNase L reduced endothelial pyroptosis, supporting a key role. Mechanistically, RNase L overactivation suppressed the m6A methyltransferase METTL3, lowering TXNIP mRNA m6A methylation. Reduced TXNIP m6A methylation decreased its degradation, raising TXNIP expression and amplifying pyroptotic signaling. In STZ-induced diabetic mice, oral EA significantly reduced skin pyroptosis and improved wound healing.

Conclusions: Hyperglycemia-driven OAS/RNase L activation may increase endothelial susceptibility to pyroptosis by disrupting METTL3-dependent TXNIP m6A methylation. Pharmacologic RNase L inhibition may attenuate inflammatory pyroptosis and promote wound repair under diabetic conditions. The OAS/RNase L–METTL3–TXNIP axis may represent a potential therapeutic target in diabetic wound healing.

Oral 3. Combined Control of Modifiable Risk Factors and Risk of Incident Lower-Limb Ulceration in Diabetes: A Prospective UK Biobank Study

Authors: Peishan Li, Lixin Guo, Qi Pan

Background: Lower-limb ulceration (LLU) is an important diabetic complication. This study examined the association of combined modifiable risk factor control with incident LLU and estimated the population-attributable burden of each uncontrolled risk factor.

Methods: The analysis drew on the UK Biobank prospective cohort, including 28,268 participants with diabetes. Based on relevant guidelines, eight modifiable risk factors were evaluated: obesity, blood pressure, glucose, LDL cholesterol, kidney function, physical activity, smoking, and diet quality. Participants were grouped by the number of factors at target: low (≤2), medium (3-5), and high (≥6). The endpoint was incident LLU during follow-up, with death or last follow-up as censoring. Survival analysis and Cox proportional hazards models were used to assess joint and individual associations; population-attributable fraction (PAF) was calculated.

Results: Over a median 13.6 years of follow-up, 1,130 participants (4.0%) developed LLU. Higher joint control was associated with higher LLU-free survival (log-rank P<0.001). Compared with the low-control group, the medium- and high-control groups had 33% and 60% lower LLU risk, respectively; each additional controlled factor was associated with approximately 20% lower LLU risk. PAF analysis identified poor obesity control as carrying the highest population-attributable burden, with a PAF of 37.7%.

Conclusions: More comprehensive control of modifiable risk factors is associated with lower LLU risk in diabetes, with weight and obesity management appearing to be important targets.

Poster 2. Patterns of Inflammatory Score Change and Risk of Incident Diabetes: A Longitudinal Study Using CHARLS

Authors: Yanxiang Luo, Han Li, Hongjian Gong, Lixin Guo, Qi Pan

Objective: Using the China Health and Retirement Longitudinal Study (CHARLS), this study described two-time-point patterns of inflammatory status and examined their association with new-onset diabetes risk.

Methods: Change in inflammatory score between Wave 1 (2011) and Wave 3 (2015) was the exposure. The score was calculated as the sum of Z-scores of C-reactive protein and white blood cell count. Incident diabetes was assessed at Wave 3 (2015) and Wave 4 (2018). A longitudinal targeted maximum likelihood estimation approach was used to assess the association of different inflammatory patterns with new-onset diabetes.

Results: 4,305 participants were included (2,404 female, 55.84%; median baseline age 58). Over 7 years, 730 participants (17.0%) developed new-onset diabetes. Four inflammatory patterns were identified: low-stable, high-stable, rising, and declining. After multivariable adjustment, the high-stable pattern was associated with significantly higher new-onset diabetes risk (RR=1.430, 95% CI: 1.204-1.698) relative to the low-stable pattern; E-value was 2.21. A sensitivity analysis with Wave 4-incident diabetes (n=150) showed positive effect estimates in the high-stable group across adjusted models, with lower precision. Subgroup analyses did not identify statistically significant effect modifiers, and neither multiplicative nor additive interaction tests reached significance.

Conclusions: Persistently elevated inflammatory scores are associated with significantly higher risk of new-onset diabetes.

Poster 3. Endogenous Fasting C-Peptide Recovery and Deterioration of Sudomotor Small-Fiber Nerve Function in Diabetes: A Real-World Study

Authors: Qingyun Cai, Lixin Guo, Qi Pan

Objective: This study examined the relationship between endogenous fasting C-peptide recovery (ΔFCP) and deterioration of sudomotor small-fiber nerve function in diabetes, assessed for a threshold effect, and analyzed whether the association was complication-specific.

Methods: A retrospective real-world cohort of 288 hospitalized adults with diabetes was analyzed; all participants had at least two fasting C-peptide measurements and Sudoscan electrochemical skin conductance (ESC) assessments. The primary endpoint, sudomotor small-fiber nerve function deterioration, was defined as a ≥15% drop in foot ESC from baseline. Large-fiber neuropathy (LFN) progression was assessed by nerve conduction studies; diabetic kidney disease (DKD) progression by estimated glomerular filtration rate and urine albumin-to-creatinine ratio. Cox proportional hazards models were used to analyze ΔFCP and each outcome; restricted cubic spline (RCS) analysis explored dose-response, with the maximum selected rank statistic identifying the optimal cut-point, supplemented by subgroup, landmark, and sensitivity analyses.

Results: Median follow-up was 2.2 years. Higher ΔFCP was independently associated with reduced risk of sudomotor small-fiber nerve function deterioration, but not with LFN or DKD progression. Compared with the lowest ΔFCP tertile, the highest tertile showed a significant risk reduction (adjusted HR=0.31, 95% CI: 0.14-0.69, P<0.001). RCS analysis suggested a non-linear, threshold-like dose-response pattern. The maximum selected rank statistic identified 126.8 pmol/L as the optimal cut-point: at ΔFCP ≥126.8 pmol/L, sudomotor small-fiber deterioration risk was reduced by 66% (HR=0.34, 95% CI: 0.17-0.69, P<0.001), with the protective effect remaining robust in landmark analysis excluding first-year events and multiple sensitivity analyses. Mediation analysis indicated that baseline FCP contributed minimally (~2%) to the protective association. Subgroup analysis suggested that patients with baseline diabetic peripheral neuropathy, hypertension, or cardiovascular disease derived greater relative benefit, in a “higher risk, higher benefit” pattern.

Conclusions: In this real-world diabetes cohort, endogenous fasting C-peptide recovery was associated with a clinically meaningful reduction in progression of sudomotor small-fiber dysfunction, in a threshold-dependent manner that is largely independent of baseline β-cell reserve.

Poster 4. Kangfuxin Solution for Diabetic Peripheral Neuropathy: A Randomized Controlled Trial

Authors: Xiuqi Qiao, Li Liu, ZhuYi Jiang, Lixin Guo, Qi Pan

Background: Kangfuxin solution is a traditional Chinese medicine preparation widely used in clinical practice, but its effect on neuropathic symptoms and nerve conduction in diabetic peripheral neuropathy (DPN) has not been fully characterized. This trial evaluated the efficacy and safety of topical Kangfuxin solution in DPN.

Methods: A single-center, randomized, controlled design randomized DPN patients 1:1 to Kangfuxin or placebo. All participants applied 50 mL of the assigned solution on gauze to both lower limbs under cling film for 20 minutes daily for 2 weeks. Outcomes, assessed at baseline and after treatment, included the Toronto Clinical Neuropathy Score (TCSS), nerve conduction velocity (NCV), inflammatory markers (CRP, TNF-α, IL-6), and glycemic parameters.

Results: 73 patients were enrolled (42 male [57.5%], 31 female [42.5%]; mean age 66.85 ± 8.70). After 2 weeks, the Kangfuxin group showed significant within-group improvement in total TCSS, symptom score, and sensory test scores, with significantly lower total and symptom scores versus placebo (all P<0.05). For nerve conduction, sensory conduction velocity in the common peroneal and tibial nerves improved from baseline, and post-treatment tibial nerve conduction velocity favored Kangfuxin over placebo. Inflammatory markers and adverse event rates did not differ significantly between groups; only two skin allergy events were reported in the Kangfuxin group.

Conclusions: Short-term topical Kangfuxin solution may improve clinical symptoms and selected nerve conduction parameters (tibial sensory NCV) in DPN, with a favorable safety profile.

Obesity Research

Oral 4. Impact of New Obesity Definitions on Prevalence and Health Outcomes

Authors: Xiuqi Qiao, Dongni Yu, Lixin Guo, Qi Pan

Objective: The European Association for the Study of Obesity (EASO) and The Lancet Diabetes & Endocrinology have recently proposed new diagnostic frameworks for obesity. This study compared obesity prevalence and clinical outcomes under different definitions.

Methods: Using UK Biobank data and updated diagnostic criteria, the study described prevalence differences across definitions, compared obesity-related dysfunction, and stratified by sex and ethnicity. Adjusted Cox proportional hazards models estimated associations of each obesity subtype with T2DM, cardiovascular events, end-stage renal disease (ESRD), and all-cause mortality.

Results: 498,353 participants were included (median age 58; 54.4% female). EASO and Lancet frameworks classified 29.6% and 63.4% of participants as having obesity, exceeding the WHO BMI-based definition by 4.8% and 38.6%, respectively. Hypertension, metabolic disorders, and musculoskeletal conditions were the most common obesity-related dysfunctions, with differences across sex and ethnicity and a notable burden in Asian populations. Notably, “overweight” defined by EASO or Lancet criteria was not consistently a risk factor, and in some analyses was associated with a protective signal. By contrast, “clinical obesity” under the Lancet criteria showed the highest risk of progression to severe outcomes among all obesity subtypes: T2DM (HR=12.33, 95% CI: 11.74-12.96), cardiovascular events (HR=4.02, 95% CI: 3.89-4.16), ESRD (HR=7.13, 95% CI: 6.11-8.33), and all-cause mortality (HR=3.07, 95% CI: 2.99-3.15), all exceeding risks associated with EASO- and WHO-defined obesity.

Conclusions: The new diagnostic frameworks substantially increase obesity detection, particularly among Asian populations. “Overweight” under EASO or Lancet criteria does not necessarily confer higher health risk. The choice of diagnostic framework directly affects risk stratification and supports treatment decisions that move beyond body weight to consider body composition.

Poster 5. Effect of Anti-Obesity Medications on Body Fat Distribution: A Network Meta-Analysis of Randomized Controlled Trials

Authors: Xiuqi Qiao, Weihao Wang, Jiaming Cao, Lixin Guo, Qi Pan

Background: Pharmacotherapy is a potential approach to weight reduction in overweight and obese populations, but evidence on its effects on regional fat distribution is limited.

Methods: PubMed, Embase, and the Cochrane Library were systematically searched for weight-loss medication RCTs published through 23 May 2023. Primary outcomes were changes in visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT); secondary outcomes were changes in body weight and waist circumference. A frequentist random-effects network meta-analysis was conducted in STATA 14.0.

Results: 39 publications covering 41 RCTs and 2,741 patients were included (mean follow-up 29.4 weeks). Both GLP-1 receptor agonists (GLP-1 RAs) and SGLT-2 inhibitors reduced VAT (standardized mean difference -0.90 and -0.66, respectively); only GLP-1 RAs reduced SAT (-1.01). Naltrexone-bupropion, GLP-1 RAs, SGLT-2 inhibitors, and metformin all reduced body weight (-5.60 kg, -4.73 kg, -3.20 kg, and -1.93 kg, respectively). GLP-1 RAs, metformin, SGLT-2 inhibitors, and naltrexone-bupropion all reduced waist circumference.

Conclusions: GLP-1 RAs may outperform other anti-obesity medications in reducing both VAT and SAT, while SGLT-2 inhibitors may have a particular advantage in reducing VAT. Clinicians may select anti-obesity medications based on a patient’s fat distribution profile.

Conclusion

From real-world clinical evidence to mechanistic exploration, and from novel intervention strategies to risk prevention frameworks, the nine studies presented at IDF-WPR 2026 by Prof. Lixin Guo and Prof. Qi Pan’s team outline a research continuum spanning diabetes development and complications management. These Chinese contributions—from DPNP treatment adherence considerations, the 5:2 MR advantage in metabolic syndrome, the OAS/RNase L axis as a wound healing target, to combined modifiable risk factor control for limb-ulcer prevention—offer distinctive perspectives for global diabetes prevention and care. The team is expected to deliver further breakthroughs, and Chinese diabetes research is poised to maintain a growing voice on the international stage.

0
0
Loading